4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ascletis Pharma Inc. (1672) operates in the Biotechnology industry and is headquartered in Wan Chai, Hong Kong with about 217 employees. Its market capitalization is roughly HK$9 billion. In the fiscal year ended 2025-12-31, 1672 reported CNY 2M in revenue and (CNY 360M) in net income.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus.
Interactive charts & full statements → Open the 1672 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 2M | CNY 1M | CNY 57M | CNY 54M | — |
| Gross Profit | CNY 0M | CNY 1M | CNY 26M | (CNY 25M) | — |
| Operating Income (EBIT) | (CNY 446M) | (CNY 382M) | (CNY 300M) | (CNY 340M) | — |
| Net Income | (CNY 360M) | (CNY 301M) | (CNY 145M) | (CNY 315M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 2.1B | CNY 2.1B | CNY 2.5B | CNY 2.7B | — |
| Total Liabilities | CNY 132M | CNY 158M | CNY 149M | CNY 117M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1672 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms